# Capsule Endoscopy > Capsule endoscopy for NEET-SS Gastroenterology: obscure bleeding first-line role, patency capsule rules, yield factors and small bowel Crohn use. - Canonical URL: https://prepelephant.com/topics/neet-ss/medical-gastroenterology/capsule-endoscopy-ss - Exam / course: NEET-SS · Subject: Medical Gastroenterology - Publisher: PrepElephant (https://prepelephant.com) — Prepared and reviewed by the PrepElephant Academic Review Team - First published: 2026-10-02 - Last updated: 2026-10-02 - How to cite: "Capsule Endoscopy", PrepElephant, https://prepelephant.com/topics/neet-ss/medical-gastroenterology/capsule-endoscopy-ss ## Direct answer A camera the size of a large vitamin pill, swallowed with a sip of water, transmits two images per second for roughly 8 hours across the small bowel — and after negative bidirectional endoscopy it becomes the first-line investigation of obscure gastrointestinal bleeding, outperforming every other modality in that niche. Its non-bleeding indications are suspected small bowel Crohn's disease (after ileocolonoscopy and cross-sectional imaging), complications of coeliac disease, and suspected small bowel tumours; its governing contraindication is known or suspected obstruction, which is why patients with Crohn's strictures or prior radiation first swallow a patency capsule that dissolves if it cannot pass. Yield is maximised by performing the study close to an active bleeding episode, with a purged bowel and prokinetic-adjusted gastric emptying in selected patients. Findings are graded P1 (uncertain relevance) and P2 (highly relevant — bleeding, angioectasia, ulceration, tumour), and a positive localisation then steers device-assisted enteroscopy — antegrade or retrograde — to the lesion for biopsy or haemostasis. ## What you must remember - **The obscure bleeding ladder:** persistent or recurrent bleeding (overt or iron-deficiency anaemia) with negative upper endoscopy and colonoscopy defines obscure bleeding; capsule endoscopy precedes deep enteroscopy because it is non-invasive and localises the bleeding site that determines the enteroscope's route. - **Timing is yield:** performed within days of overt rebleeding or during ongoing iron deficiency, diagnostic yield rises steeply — a capsule deployed three months after a single melaena finds far less than one deployed in the actively bleeding window. - **Patency capsule logic:** a dissolvable capsule of the same dimensions with a radio-opaque tag; safe excretion confirms the lumen will pass the real capsule, permitting the study in stricturing Crohn's disease, prior radiation or adhesive disease. - **Retention definition:** capsule retained beyond 2 weeks requiring medical, endoscopic or surgical retrieval; overall risk roughly 1–2 per cent in obscure bleeding but up to around 5 per cent in suspected Crohn's disease — the reason patency testing exists. - **Small bowel Crohn's role:** after a normal ileocolonoscopy and cross-sectional enterography, capsule endoscopy identifies small bowel ulceration beyond the reach of the colonoscope and can reclassify disease extent — never before the stricture question is settled. - **Coeliac complications:** refractory disease, ulcerative jejunitis and suspected enteropathy-associated lymphoma are assessed by capsule before push or device-assisted enteroscopy with targeted biopsy. - **Preparation evidence:** a 2-litre polyethylene glycol preparation with simethicone improves mucosal visibility over fasting alone; routine prokinetics are not standard but are considered in gastroparesis or poor transit. - **Reading discipline:** a full read takes 30–60 minutes; roughly 10 per cent of significant lesions are missed within camera blind spots (behind folds, in rapid transit segments), so a negative capsule in iron-deficiency bleeding does not end the workup — repeat capsule, CT enterography or enteroscopy follow. - **Indian access note:** with capsule endoscopy concentrated in metropolitan centres and paid largely out-of-pocket, patient selection matters disproportionately; the patency capsule adds cost but converts the Crohn's patient's study from a gamble into a protocol. ## A worked obscure-bleeding pathway A 62-year-old with recurrent melaena and haemoglobin dipping to 6.5 has had a normal upper endoscopy (including a second-look with a colonoscope to the ligament of Treitz) and a normal colonoscopy with good preparation. Obscure overt bleeding, anaemia ongoing — the window is favourable. Iron infusion and capsule within the week: the study shows an actively oozing angioectasia in the proximal jejunum, timed to its transit quartile, which places it within antegrade single-balloon enteroscopy reach. Argon plasma coagulation at enteroscopy closes the episode, with follow-up haemoglobin at three months confirming cure. Had the capsule been negative, the next steps were a repeat capsule during the next bleed, then CT enterography looking for a vascular blush or a small tumour — the sequence matters, and repeating the cheap and invasive tests is not part of it. This is the algorithm that converts "obscure" into "managed", and each branch is a legitimate single-best-answer stem. ## How the exam frames it Three questions dominate. Which investigation after negative bidirectional endoscopy in obscure bleeding — capsule endoscopy, not enteroscopy first, not CT first. Which patients need a patency capsule — known or suspected strictures, Crohn's disease, prior pelvic radiation. And what limits the technology — blind spots with a roughly 10 per cent miss rate, no biopsy, no therapy, retention risk. The Indian viva adds the health-systems angle: how to sequence investigations when the capsule is the family's out-of-pocket expense, and why that makes correct first-time sequencing an ethical as much as a technical skill. ## Frequently asked questions ### When is capsule endoscopy the first-line investigation? In obscure gastrointestinal bleeding — persistent or recurrent bleeding or iron-deficiency anaemia after negative upper endoscopy and colonoscopy — where it both detects and localises the lesion. ### How is capsule retention prevented in stricturing disease? By a preliminary patency capsule of identical dimensions that dissolves if held up; safe excretion within about 30 hours permits the diagnostic study. ### How does capsule endoscopy fit into suspected Crohn's disease? After a normal ileocolonoscopy and cross-sectional imaging, it detects small bowel ulceration beyond colonoscopic reach — after stricture exclusion with patency testing. ### What factors raise diagnostic yield in obscure bleeding? Performance close to an active bleeding episode or during ongoing anaemia, adequate bowel preparation, and complete small bowel transit with careful full-length reading. ### What are the limitations of capsule endoscopy? No biopsy or therapy, blind-spot miss rate of roughly 10 per cent, inability to insufflate or inspect behind folds, and retention risk of 1–2 per cent overall (higher in Crohn's disease).